Gloria Matthews, DVM, Joins Histogenics as Chief Medical Officer
Former Senior Director, Research and Development At Genzyme/Sanofi
Life Science Partner has recruited Gloria Matthews, DVM, PhD to become Chief Medical Officer at Histogenics. In her new role Matthews will report directly to the Chief Executive Officer, Adam Gridley, and will serve as the senior physician within Histogenics responsible for clinical direction, product strategy, medical affairs, and strategic oversight of the global clinical trials for the Company’s products.
Mathews joins Histogenics from Genzyme/Sanofi where she led the global development team focused on two autologous cell therapies for cartridge repair including Carticel. She is a well published and leader in the field of regenerative medicine, with a corporate background that integrates fundamental science, clinical development, and global regulatory expertise.
“As a globally recognized thought leader for orthopedic R&D, Matthews has led global teams focused on regenerative medicine including US, Europe and Asia,” noted Tom Callaway, MD, President of Life Science Partner. “With her deep knowledge of cartilage regeneration and its challenges, Matthews will bring her considerable experience to help commercialize Histogenics’ portfolio.”
Matthews received her Bachelor of Science degree in biochemistry and Animal Science, as well as her PhD in Cell/Matrix Biology and DVM from Cornell University.
Leave a ReplyWant to join the discussion?
Feel free to contribute!